ShockWave Medical, Inc.
SWAV
Peringkat dalam Saham
#1722
ShockWave Medical, Inc. is a medical technology firm that specializes in the... ShockWave Medical, Inc. is a medical technology firm that specializes in the development and global commercialization of intravascular lithotripsy (IVL) systems. This innovative approach is designed to treat calcified plaque in individuals affected by peripheral vascular, coronary vascular, and heart valve conditions. The company's product offerings include the M5 catheter for addressing above-the-knee peripheral artery disease, the C2 catheter specifically for coronary artery disease, and the S4 catheter, which targets below-the-knee peripheral artery disease. ShockWave Medical serves a professional clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, leveraging both direct sales teams and distribution partners. The organization was founded in 2009 and is based in Santa Clara, California.
Harga Saham
$334.75
Terakhir disinkronkan: 2024-05-30
Kapitalisasi Pasar
$12.46B
Perubahan (1 hari)
-0.02%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan ShockWave Medical, Inc. (SWAV)
Kategori
Healthcare
Rasio P/S untuk ShockWave Medical, Inc. (SWAV)
Rasio P/S per October 2026 TTM: 17.21
Menurut laporan keuangan dan harga saham terbaru dari ShockWave Medical, Inc., rasio P/S saat ini (TTM) adalah 17.21. Pada akhir 2022, rasio P/S perusahaan adalah 15.07.
Riwayat rasio P/S untuk ShockWave Medical, Inc. dari 2017 hingga 2026
Rasio P/S pada akhir setiap tahun
| Tahun | Rasio P/S | Mengubah |
|---|---|---|
| 2026 (TTM) | 17.21 | 79.65% |
| 2023 | 9.58 | -36.45% |
| 2022 | 15.07 | -42.89% |
| 2021 | 26.39 | -47.87% |
| 2020 | 50.63 | 106.99% |
| 2019 | 24.46 | -63.45% |
| 2018 | 66.92 | -80.69% |
| 2017 | 346.49 | 0.00% |
Rasio P/S untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/S | Perbedaan Rasio P/S | Negara |
|---|---|---|---|
| 3.82 | -77.78% |
US
|
|
| 2.78 | -83.82% |
IE
|
|
| 4.18 | -75.72% |
US
|
|
| 2.97 | -82.74% |
US
|
|
| - | - |
DE
|
